Table 5.
Associations Between Clinicopathologic Parameters and OS in HER2-Positive Breast Cancer
| Variables | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age (years) | ||||
| ≤ 35 | 1 | / | ||
| > 35 | 0.42 (0.05–3.80) | 0.420 | / | / |
| Tumor stage | ||||
| pT1 | 1 | 1 | ||
| pT2-4 | 3.72 (0.46–30.30) | 0.191 | 1.93 (0.21–17.55) | 0.559 |
| Tumor differentiation | ||||
| G1-2 | 1 | / | ||
| G3 | 1.81 (0.49–6.71) | 0.367 | / | / |
| Lymph node involvement | ||||
| pN0 | 1 | 1 | ||
| pN1-3 | 3.72 (0.76–18.18) | 0.085 | 6.39 (1.28–31.90) | 0.038 |
| HR status | ||||
| Positive | 1 | / | ||
| Negative | 1.04 (0.28–3.86) | 0.950 | / | / |
| Ki67 | ||||
| Low (≤30%) | 1 | / | ||
| High (>30%) | 0.73 (0.20–2.65) | 0.636 | / | / |
| Surgery | ||||
| Mastectomy | 1 | / | ||
| Breast-conserving surgery | 0.78 (0.09–6.58) | 0.823 | / | / |
| Radiotherapy | ||||
| Yes | 1 | / | ||
| No | 0.60 (0.15–2.43) | 0.471 | / | / |
| Endocrine therapy | ||||
| Yes | 1 | / | ||
| No | 2.01 (0.50–8.06) | 0.318 | / | / |
| NLR | ||||
| ≤1.69 | 1 | 1 | ||
| >1.69 | 2.93 (0.60–14.29) | 0.165 | 3.10 (0.35–27.46) | 0.256 |
| PLR | ||||
| ≤110 | 1 | 1 | ||
| >110 | 4.84 (0.60–40.0) | 0.105 | 2.91 (0.25–33.28) | 0.390 |
| SII | ||||
| ≤442 | 1 | 1 | ||
| >442 | 6.54 (1.34–32.26) | 0.009 | 2.32 (1.25–4.31) | 0.01 |
Abbreviations: OS, overall survival; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; CI, confidence interval; T, tumor; G, grade; N lymph-node; HR, hormone receptor; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; SII, systemic immune-inflammation index.